Mantle Cell Lymphoma
From the Journals
Daratumumab disappoints in non-Hodgkin lymphoma trial
The drug, used in multiple myeloma, was safe but ineffective in patients with non-Hodgkin lymphoma.
From the Journals
Combo appears to overcome aggressive L-NN-MCL
Two case studies highlight the role that P53 gene status plays in prognosis and treatment.
News
FDA grants BI-1206 orphan designation for MCL
BI-1206 is under investigation in a phase 1/2a study.
From the Journals
Autologous transplant linked to PFS benefit in MCL
No overall survival benefit was detected in this retrospective study, in contrast to a previous analysis.
News
Zanubrutinib receives breakthrough designation for MCL
The Bruton’s tyrosine kinase inhibitor was evaluated in a phase 2 trial.
From the Journals
Adding umbralisib to ibrutinib produced responses in MCL, CLL
The doublet regimen “is the first successful combination for two drugs targeting B-cell blockade.”
Conference Coverage
Lenalidomide maintenance improves MCL survival after ASCT
SAN DIEGO – PFS was better post transplant with lenalidomide maintenance, but it’s too early to know whether OS will be improved.
From the Journals
Cortactin expression aids in CLL-MCL differential
Cortactin, a cytoskeleton-remodeling adapter protein, is expressed on most CLL cells, but not similar-appearing MCL cells.
Conference Coverage
Relapsed MCL: Options for treatment
There are a number of treatment options for relapsed MCL, but BTK inhibitors are particularly useful.
From the Journals
First-line bortezomib prolongs survival in MCL
The survival benefits are promising with the addition of bortezomib, but there was no significant difference among high-risk patients.
From the Journals
Ibrutinib discontinuation harms survival in CLL
A single-institution study examines the impact of early dose reduction of ibrutinib in non-Hodgkin lymphoma and CLL.